Literature DB >> 28686007

Imaging of primary liver tumors with positron-emission tomography.

Alexander R Haug1.   

Abstract

INTRODUCTION: The use of positron-emission tomography (PET) with fluorodeoxyglucose (FDG), 11C-acetate and radio-labelled choline such as 11C-choline or 18F-fluorocholine in the diagnosis of hepatocellular carcinoma (HCC), for risk stratification or therapy monitoring has emerged. This review aims to summarize the published results dealing with this issue. EVIDENCE ACQUISITION: PubMed database was searched until February 2017. Sensitivities, specificities, progression-free survival (PFS), survival and hazard ratios (HR) are reported. EVIDENCE SYNTHESIS: Seventy-one studies were included. Most studies are dealing with the diagnostic value of FDG PET (N.=21), 11C-acetate PET (N.=11), and choline PET (N.=8). The results indicate a homogenously higher sensitivity for 11C-acetate and choline PET as compared to FDG PET in the diagnosis of primary or recurrent HCC. This is particularly true for well differentiated HCC, which tend to have higher uptake of 11C-acetate and radio-labelled choline. Contrary, poorly differentiated HCC are more often FDG-positive than well differentiated HCC. Sixteen studies are evaluating the prognostic value of FDG PET for surgery or liver transplantation. The studies found a significant worse prognosis in terms of time to recurrence, PFS, and survival in FDG-positive HCC as compared to FDG-negative ones. Sixteen studies are reporting about the prognostic value of FDG PET and one about 18F-fluoroethylcholine PET for palliative treatment. Most of these studies indicate a significant shorter PFS and survival in FDG-positive HCC for various treatments.
CONCLUSIONS: Whereas FDG PET has only a limited role in the diagnosis of HCC, it provides valuable prognostic information for liver surgery, transplantation and palliative treatment. 11C-acetate and choline PET have a higher sensitivity in the diagnosis of HCC.

Entities:  

Mesh:

Year:  2017        PMID: 28686007     DOI: 10.23736/S1824-4785.17.02994-6

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN: 1824-4785            Impact factor:   2.346


  8 in total

1.  90Y-radioembolization of hepatocellular carcinoma from a theranostic perspective: towards a personalized approach.

Authors:  Luca Filippi; Orazio Schillaci; Oreste Bagni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-07       Impact factor: 9.236

Review 2.  Microvascular Invasion in HCC: The Molecular Imaging Perspective.

Authors:  Vincenzo Cuccurullo; Giuseppe Danilo Di Stasio; Giuseppe Mazzarella; Giuseppe Lucio Cascini
Journal:  Contrast Media Mol Imaging       Date:  2018-10-04       Impact factor: 3.161

Review 3.  18F-fludeoxyglucose positron emission tomography for diagnosis of HCC: implications for therapeutic strategy in curative and non-curative approaches.

Authors:  Arno Kornberg; Helmut Friess
Journal:  Therap Adv Gastroenterol       Date:  2019-03-19       Impact factor: 4.802

4.  PET Imaging of Hepatocellular Carcinomas: 18F-Fluoropropionic Acid as a Complementary Radiotracer for 18F-Fluorodeoxyglucose.

Authors:  Jing Zhao; Zhanwen Zhang; Dahong Nie; Hui Ma; Gongjun Yuan; Shu Su; Shaoyu Liu; Sheng Liu; Ganghua Tang
Journal:  Mol Imaging       Date:  2019 Jan-Dec       Impact factor: 4.488

5.  Clinical impact of anatomical resection on long-term outcomes after hepatectomy for primary solitary hepatocellular carcinoma with or without preoperative positron emission tomography positivity.

Authors:  Chan Woo Cho; Jong Man Kim; Beom-Hui Lee; Dong-Shik Lee; Sung-Su Yun; Gyu-Seong Choi; Jae-Won Joh
Journal:  Ann Transl Med       Date:  2020-11

6.  Different Features of 18F-FAPI, 18F-FDG PET/CT and MRI in the Evaluation of Extrahepatic Metastases and Local Recurrent Hepatocellular Carcinoma (HCC): A Case Report and Review of the Literature.

Authors:  Donghe Chen; Chengdong Chang; Yafei Zhang; Shuye Yang; Guolin Wang; Lili Lin; Xin Zhao; Kui Zhao; Xinhui Su
Journal:  Cancer Manag Res       Date:  2022-09-05       Impact factor: 3.602

7.  When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma.

Authors:  Abu Bakar Hafeez Bhatti; Ammal Imran Qureshi; Rizmi Tahir; Faisal Saud Dar; Nusrat Yar Khan; Haseeb Haider Zia; Shahzad Riyaz; Atif Rana
Journal:  BMC Cancer       Date:  2020-08-12       Impact factor: 4.430

8.  Expression of CD4+CD25+CD127Low regulatory T cells and cytokines in peripheral blood of patients with primary liver carcinoma.

Authors:  Wenchao Zhou; Jianxin Deng; Qianmei Chen; Ruiying Li; Xiaosong Xu; Yubin Guan; Wei Li; Xiaomin Xiong; Hongwei Li; Jianpei Li; Xiangsheng Cai
Journal:  Int J Med Sci       Date:  2020-02-24       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.